Introduction: An escalating number of fatalities resulting from accidental opioid overdoses typically attributed to respiratory depression continue to define the opioid epidemic. Opioid respiratory depression results from a decrease in reflexive inspiration within the preBötzinger complex in the brainstem. Objective: Cannabinoid receptor agonism is reported to enhance opioid analgesia, yet whether cannabinoids enhance or inhibit opioid-induced respiratory depression is unknown. Methods: Studies herein sought to define the roles of cannabinoid-1 receptor (CB1R) and cannabinoid-2 receptor (CB2R) on respiratory depression using selective agonists alone and in combination with morphine in male mice. Results: Using whole body plethysmography, the nonselective CB1R and CB2R agonist (Δ9-tetrahydrocannabinol) and the CB1R synthetic cannabinoid, AM356, induced respiratory depression, whereas the well-published selective CB2 agonist, JWH 133, and the novel CB2 agonist (AM2301) did not. Moreover, a selective CB2R agonist (AM2301) significantly attenuated morphine sulfate-induced respiratory depression. Conclusion: Notably, findings suggest that attenuation of opioid-induced respiratory depression relies on CB2R activation, supporting selective CB2R agonism as an opioid adjunct therapy.
Introduction: An escalating number of fatalities resulting from accidental opioid overdoses typically attributed to respiratory depression continue to define the opioid epidemic. Opioid respiratory depression results from a decrease in reflexive inspiration within the preBötzinger complex in the brainstem. Objective: Cannabinoid receptor agonism is reported to enhance opioid analgesia, yet whether cannabinoids enhance or inhibit opioid-induced respiratory depression is unknown. Methods: Studies herein sought to define the roles of cannabinoid-1 receptor (CB1R) and cannabinoid-2 receptor (CB2R) on respiratory depression using selective agonists alone and in combination with morphine in male mice. Results: Using whole body plethysmography, the nonselective CB1R and CB2R agonist (Δ9-tetrahydrocannabinol) and the CB1R synthetic cannabinoid, AM356, induced respiratory depression, whereas the well-published selective CB2 agonist, JWH 133, and the novel CB2 agonist (AM2301) did not. Moreover, a selective CB2R agonist (AM2301) significantly attenuated morphine sulfate-induced respiratory depression. Conclusion: Notably, findings suggest that attenuation of opioid-induced respiratory depression relies on CB2R activation, supporting selective CB2R agonism as an opioid adjunct therapy.
Authors: Juan G Zarruk; David Fernández-López; Isaac García-Yébenes; María S García-Gutiérrez; José Vivancos; Florentino Nombela; Magdalena Torres; María C Burguete; Jorge Manzanares; Ignacio Lizasoain; María A Moro Journal: Stroke Date: 2011-10-20 Impact factor: 7.914
Authors: Mohab M Ibrahim; Frank Porreca; Josephine Lai; Phillip J Albrecht; Frank L Rice; Alla Khodorova; Gudarz Davar; Alexandros Makriyannis; Todd W Vanderah; Heriberto P Mata; T Philip Malan Journal: Proc Natl Acad Sci U S A Date: 2005-02-10 Impact factor: 11.205
Authors: Yingpeng Liu; Lipin Ji; Marsha Eno; Shalley Kudalkar; Ai-Ling Li; Marion Schimpgen; Othman Benchama; Paula Morales; Shu Xu; Dow Hurst; Simiao Wu; Khadijah A Mohammad; JodiAnne T Wood; Nikolai Zvonok; Demetris P Papahatjis; Han Zhou; Chandrashekhar Honrao; Ken Mackie; Patricia Reggio; Andrea G Hohmann; Lawrence J Marnett; Alexandros Makriyannis; Spyros P Nikas Journal: J Med Chem Date: 2018-09-21 Impact factor: 8.039
Authors: Spyros P Nikas; Rishi Sharma; Carol A Paronis; Shashank Kulkarni; Ganesh A Thakur; Dow Hurst; JodiAnne T Wood; Roger S Gifford; Girija Rajarshi; Yingpeng Liu; Jimit Girish Raghav; Jason Jianxin Guo; Torbjörn U C Järbe; Patricia H Reggio; Jack Bergman; Alexandros Makriyannis Journal: J Med Chem Date: 2014-12-16 Impact factor: 7.446
Authors: David P Finn; Simon Haroutounian; Andrea G Hohmann; Elliot Krane; Nadia Soliman; Andrew S C Rice Journal: Pain Date: 2021-07-01 Impact factor: 7.926